Strides Pharma Science Limited (BOM:532531)
1,042.95
+15.60 (1.52%)
At close: Jun 5, 2026
Strides Pharma Science Employees
Strides Pharma Science had 3,301 employees as of March 31, 2025. The number of employees increased by 236 or 7.70% compared to the previous year.
Employees
3,301
Change (1Y)
236
Growth (1Y)
7.70%
Revenue / Employee
14.72M INR
Profits / Employee
1.68M INR
Market Cap
96.28B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 3,301 | 236 | 7.70% |
| Mar 31, 2024 | 3,065 | 215 | 7.54% |
| Mar 31, 2023 | 2,850 | 203 | 7.67% |
| Mar 31, 2022 | 2,647 | 257 | 10.75% |
| Mar 31, 2021 | 2,390 | -579 | -19.50% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| FDC Limited | 6,857 |
| Jubilant Pharmova | 5,547 |
| CORONA Remedies | 4,500 |
| Granules India | 4,066 |
| Caplin Point Laboratories | 3,966 |
| Procter & Gamble Health | 1,326 |
| Viyash Scientific | 1,244 |
| Sanofi India | 1,097 |
Strides Pharma Science News
- 19 days ago - Strides Pharma Science Transcript: Q4 25/26 - Transcripts
- 19 days ago - Strides Pharma Science Quarterly report: Q4 2026 - Filings
- 19 days ago - Strides Pharma Science Slides: Q4 2026 - Filings
- 6 weeks ago - Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77% - Business Upturn
- 2 months ago - Strides Pharma shares over 3% after acquiring generic brands from Sandoz for US$ 12 million - Business Upturn
- 2 months ago - Strides Pharma Science acquires generic brands from Sandoz for US$ 12 million - Business Upturn
- 4 months ago - Strides Pharma Science Transcript: Q3 25/26 - Transcripts
- 4 months ago - Strides Pharma Science Quarterly report: Q3 2026 - Filings